tiprankstipranks
Eckert & Ziegler to supply POINT Biopharma with Actinium-225
The Fly

Eckert & Ziegler to supply POINT Biopharma with Actinium-225

Eckert & Ziegler have signed an agreement on the supply of Actinium-225. Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands. "Since our early days, POINT has placed a significant focus on radioligand manufacturing and isotope supply, two areas we believe have been overlooked by many in the industry," said Joe McCann, Ph.D., CEO of POINT Biopharma. "This agreement with Eckert & Ziegler contributes to our continued research and development with Actinium-225, an exciting therapeutic isotope. We are looking forward to launching our first Ac-225 phase 1 trial for the next generation PSMA-targeted PNT2001 program later this year."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on PNT:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles